Enterprise Value

5.339B

Cash

431.1M

Avg Qtr Burn

-135.2M

Short % of Float

7.27%

Insider Ownership

0.07%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
SKYTROFA (TransCon hGH) (lonapegsomatropin) Details
Pediatric growth hormone deficiency

Approved

Quarterly sales

TransCon PTH Details
Adult hypoparathyroidism

NDA

Resubmission

TransCon hGH Details
Adult growth hormone deficiency

Phase 3

Data readout

TransCon hGH Details
Turner syndrome

Phase 2

Data readout

TransCon IL-2 B/y Details
Solid tumor/s, Cancer

Phase 2

Data readout

Phase 2

Data readout

TransCon CNP Details
Achondroplasia

Phase 2

Data readout

Phase 2

Initiation